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Objective: Primary cardiac sarcomas are rare tumors carrying poor prognosis. Resection remains the primary
therapy. Especially in recent years, chemotherapy and radiation have been used adjunctively.
Methods: All patients (n¼ 27) surgically treated for primary cardiac sarcoma at two tertiary referral centers from
January 1990 to January 2006 were retrospectively reviewed.
Results: There were 13 women and 14 men, with 26 resections and 1 palliative debulking performed. Cardiac
explantation was necessary in 8 cases because of tumor location. Concomitant valve surgery (repair or replace-
ment) or coronary artery bypass grafting was performed in 9 and 3 patients, respectively. Synchronous or staged
resections of associated pulmonary metastases were performed in 6 and 2 patients, respectively. Operative mor-
tality was 7.4% (2/27). Preoperative or postoperative chemotherapy was administered to 16 and 19 patients, re-
spectively. At follow-up (median 22 months, range, 2–119 months), 12 patients were alive, with 7 tumor free.
Among patients who underwent resection with curative intent and survived surgery (n ¼ 24), median survival
was 23.5 months (range 4–119 months). Patients who underwent surgical resection, radiofrequency ablation,
or radiation treatment for tumor recurrence (local or metastatic, n ¼ 7) had median survival of 47 months (range
16–119 months), whereas patients with no further intervention for recurrent disease (n ¼ 7) had median survival
of 25 months (range 8–34 months).
Conclusions: Multimodal therapy can achieve reasonable survival for patients with resected cardiac sarcomas.
Patients with local tumor recurrence or metastatic disease may still benefit from aggressive treatment.
Acquired Cardiovascular Disease Bakaeen et alPrimary malignant tumors of the heart and great vessels are
extremely rare. Sarcoma represents more than two thirds of
these malignancies and usually has an aggressive and fatal
course.1,2 The bleak prognosis of this disease has been re-
ported in several small case series and individual reports.3-10
Our institution’s review of 21 patients treated from 1964
to 1989 reiterated the poor prognosis of the disease, with
a median survival of only 11 months.11 A survival advantage
was noted for patients who underwent aggressive surgical
resection and clearing of all disease relative to those who re-
ceived palliative treatment (median 24 vs 10 months).11
More recently, a collaborative effort between The Univer-
sity of Texas M. D. Anderson Cancer Center and the Meth-
odist Hospital has been adopted. This new treatment
includes surgical resection with adjunctive chemotherapy
and radiation therapy. We review our evolving experience
with aggressive multimodality treatment of cardiac sarco-
mas.
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Patients
With institutional review board approval and with waiver of individual
consent granted, a retrospective review was performed of all patients who
underwent surgical treatment of cardiac sarcoma from January 1990 to Jan-
uary 2006. All patients with histologically proven primary sarcoma involv-
ing cardiac chambers or great vessels were included. All patients were seen
by the senior author (M.J.R.). Patients who were referred for surgery but
turned down, estimated by M.J.R. to be 20% of referrals, were not included
in our database.
Patient charts were reviewed to document data on presenting symptoms,
preoperative workup, surgical and oncologic treatment, tumor pathologic
type, hospital course, and complications. Operative mortality was defined
to encompass any death occurring during the first 30 postoperative days
or during the same hospitalization. After hospital discharge, a multidisciplin-
ary team closely followed up patients, unless the patient opted to be fol-
lowed up closer to home with guidance from our institution. Follow-up
data to January 2006 or death were available for all patients.
Evaluation and Multimodality Treatment
Patients underwent a thorough review by a multidisciplinary team, in-
cluding medical oncologists, radiation oncologists, and cardiac surgeons.
Computed tomography, cardiac gated magnetic resonance imaging, and
echocardiography were the primary imaging modalities used by the operat-
ing surgeon to determine anatomic resectability. Positron emission tomog-
raphy and coronary angiography were performed in a selective manner.
The overall treatment plan, including the timing of various therapy
modalities, was based on a number of tumor- and patient-related factors
including resectability, tumor susceptibility to chemotherapeutic agents,
disease-free interval in cases involving recurrence, the presence and severity
of symptoms, and the physiologic status of the patient. For the purposes of
this study, complete resection was defined as an absence of gross residual
disease after resection (R0/R1). Incomplete resection was defined as the
presence of macroscopic residual disease (R2) after resection.rgery c June 2009
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All data were analyzed with SAS version 8.1 (SAS Institute, Inc, Cary,
NC). Continuous variables are reported as median and range (minimum to
maximum). Estimate of overall survival was also calculated by the Kaplan–
Meier method and expressed as percentage with 95% confidence interval.
RESULTS
Patient Profile
Between January 1990 and January 2006, a total of 27 pa-
tients underwent surgical resection for primary cardiac sar-
comas. There were 13 women and 14 men, with a median
age of 40.6 years (range 18–69 years). Signs and symptoms
included dyspnea in 24 patients (89%), arrhythmias or pal-
pitations in 14 (52%), cough in 11 (41%), chest pain in 8
(30%), and constitutional symptoms of fever, weight loss,
or night sweats in 12 (44%). Symptomatic pericardial effu-
sion was present in 5 patients (19%).
Seventeen patients (63%) had undergone previous surgi-
cal procedures at outside institutions. The median time from
previous procedure to definitive surgical treatment was 7
months (range 1–10 months).
Tumor Characteristics
The tumors were grouped according to three anatomic lo-
cations: right heart sarcomas in 17 patients (63%), left heart
sarcomas in 8 (30%), and pulmonary artery sarcomas in 2
(7%). Two patients (7.5%) had multiple tumor foci, includ-
ing 3 foci in the right atrium and right ventricle in 1 patient,
and 3 foci in the left atrium and interventricular septum
in another patient. Histologic types included angiosarcoma
in 11 patients (41%), undifferentiated high-grade sarcoma in
7 (26%), malignant fibrous histiocytoma in 4 (15%), leio-
myosarcoma in 2 (7%), synovial cell sarcoma in 2 (7%),
and chondroblastic high-grade osteosarcoma in 1 (4%).
Surgery
Median sternotomy and total cardiopulmonary bypass
with bicaval venous cannulation and aortic arterial return
were used in most cases. Two patients (7%) required hypo-
thermic circulatory arrest for resection of right atrial tumors
with extensive involvement of the superior vena cava (Table
1). Cardiac explantation with autotransplantation was
used in 8 patients (30%) because of extensive left atrial
involvement, as previously described.12,13 Reconstruction
of cardiac chambers was performed with bovine pericardium.
Great vessel repair or reconstruction was performed with
bovine pericardium in 7 patients (26%), autologous pericar-
dium in 4 (15%), Dacron polyester fabric or polytetrafluoro-
ethylene interposition grafts in 2 (7%), and cryopreserved
pulmonary artery allograft in 1 (4%). Involvement of the
right coronary artery occurred in 3 patients (11%) and re-
quired concomitant coronary artery bypass grafting. Mitral
and tricuspid repairs or replacements were performed in 8
patients (30%). One patient underwent palliative debulkingThe Journal of Thoracic and Conly because of extensive tumor involvement of the right
atrium and invasion into the posterior mediastinum. The spe-
cific operative procedures performed in each individual case
are outlined in Table 2.
Additional Pulmonary Resections
Eight patients (30%) had known pulmonary metastases at
the time of definitive cardiac resection. Five of these patients
underwent concomitant resection, and another 2 patients un-
derwent staged resections at a later date (Table 2). The re-
maining patient (patient 11) had rapid progression of his
pulmonary metastases after cardiac resection and did not un-
dergo additional surgery. The two patients with pulmonary
artery sarcomas required pneumonectomy to achieve R0 re-
section. One patient (patient 22) underwent cardiac auto-
transplantation to treat to a sarcoma involving the left
atrium, the left pulmonary veins, and hilum. A return to
the operating room was necessary for pneumonectomy be-
cause of a devitalized left lung.
Morbidity and Mortality
There were 2 perioperative deaths (7%). One patient (pa-
tient 17) who had undergone extensive resection of the right
ventricle, replacement of the tricuspid valve, and distal sep-
tal resection, died of irreversible coagulopathy and cardiac
failure on the first postoperative day. This patient had a his-
tory of chest wall radiation for lymphoma and breast cancer.
The second patient (patient 15) died on postoperative day 18
of sepsis and multiple organ failure after extensive cardiac
TABLE 1. Surgical procedures performed at our institution
Surgery Patients
Extent of resection
R0 15
R1 11
R2 1
Surgical approach and associated procedures
Explantation or reimplantation 8
Hypothermic circulatory arrest 2
Coronary artery bypass grafting 3
Great vessel repair or reconstruction 14
Valve repair or replacement 9
Tricuspid 4
Mitral 4
Pulmonary root 1
Concomitant pulmonary resection 6
Pneumonectomy 2
Lobectomy 3
Wedge resection 1
Staged pulmonary resection 2
Bilobectomy 1
Wedge resection 1ardiovascular Surgery c Volume 137, Number 6 1455
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Case
Histologic
type Primary site
Metastasis at
presentation Resection margin and operative features
Right heart sarcomas
1 Angiosarcoma RA Lung R1 resection; RA reconstruction; bilobectomy 1 mo
later
2 Angiosarcoma RA None R0 resection; RA, SVC reconstruction; TV
annuloplasty
3 Angiosarcoma RA None R0 resection
4 MFH RA Lung R0 resection, right lung wedge 32
5 HGUS RA, right PA Lung R0 resection; RA, PA reconstruction; wedge
resection 33 lesions and RFA 32 lesions in right
lung 6 mo later
6 Leiomyosarcoma RA, SVC, BCV None R1 resection; RA, SVC, BCV reconstruction
7 Synovial sarcoma RA, SVC None Palliative debulking
8 Angiosarcoma RA, extension into RCA None R1 resection; RITA to RCA bypass
9 Angiosarcoma RA, TV None R0 resection; TV replacement
10 Synovial sarcoma RA, extension into right superior PV None R0 resection; hypothermic circulatory arrest
11 Angiosarcoma RA, SVC Lung R0 resection; RA, SVC reconstruction
12 Angiosarcoma RA, RV, SVC None R0 resection; SVC reconstruction
13 Angiosarcoma RA, SVC, LA roof None R0 resection; SVC, atrial reconstruction
14 Angiosarcoma RA, SVC, RCA None R0 resection; RCA reconstruction with RITA
interposition graft
15 Angiosarcoma RA, SVC, extension into RV, RCA Lung R1 resection; hypothermic circulatory arrest; SVG to
PDA coronary bypass; RUL wedge resection
16 HGUS RA, TV, extension into RV,IVS
(3 separate tumor foci)
None R1 resection; cardiac explantation; TV excision,
replacement
17 HGUS RV, TV, IVS None R0 resection; TV excision, replacement
Left heart sarcomas
18 MFH LA Lung R0 resection; RUL resection
19 HGUS LA None R1 resection; cardiac explantation
20 HGUS LA, left superior PV None R1 resection; cardiac explantation; LA, PV
reconstruction
21 HGUS LA, right PVs None R1 resection; cardiac explantation
22 MFH LA, left PVs, hilum None R1 resection; cardiac explantation; LA, left PVs
reconstruction; MV repair
23 HGUS LA, IVS (3 separate tumor foci) None R1 resection; cardiac explantation; MV resection,
replacement
24 MFH LA, MV annulus Lung R1 resection; cardiac explantation; MV excision,
replacement; RUL wedge
25 CHGO IVS, chordae of MV None R0 resection; cardiac explantation; MV excision,
replacement
Pulmonary artery sarcomas
26 Leiomyosarcoma Main PA at bifurcation Lung R0 resection; left pneumonectomy; PA reconstruction
27 Angiosarcoma Main PA, valve None R0 resection, main PA reconstruction with
homograft; right pneumonectomy
RA, Right atrium; SVC, superior vena cava; TV, tricuspid valve; MFH, malignant fibrous histiocytoma; HGUS, high-grade undifferentiated sarcoma; PA, pulmonary artery; RFA,
radiofrequency ablation; BCV, brachiocephalic vein; RCA, right coronary artery; RITA, right internal thoracic artery; PV, pulmonary vein; LA, left atrium; RV, right ventricle; SVG,
saphenous vein graft; PDA, posterior descending coronary artery; RUL, right upper lobe; IVS, interventricular septum; MV, mitral valve; CHGO, chondroblastic high-grade oste-
osarcoma.resection of a tumor involving the right atrium and ventricle,
in addition to a wedge resection of a right upper lobe lesion.
Postoperative hemorrhage requiring surgical reexplora-
tion was necessary in 2 patients (7%). Cardiac complica-
tions included mild congestive heart failure (medically
treated) in 17 patients (63%), cardiac arrhythmias in 5
(19%), persistent complete atrioventricular block necessitat-1456 The Journal of Thoracic and Cardiovascular Suing a pacemaker placement in 1 patient (4%) and pericarditis
in 2 patients (7%). Pulmonary complications included pneu-
monia in 4 patients (15%) and pleural effusions requiring
drainage in 8 (30%). Phrenic nerve paralysis occurred in 2
patients (7%). One patient required a reoperation at 6 weeks
after his initial definitive surgery (cardiac autotransplanta-
tion) for a stricture at the superior vena cava anastomoticrgery c June 2009
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Chemotherapy and Radiotherapy
All but 1 patient received chemotherapy or radiation ther-
apy in the preoperative or postoperative setting (Table 3).
Neoadjuvant chemotherapy was administered to 16 patients
(59%) before definitive surgical management, and 19 pa-
tients (70%) received adjuvant chemotherapy. The most
common agents used were doxorubicin, ifosfamide, gemci-
tabine, and taxoterene. One patient received preoperative ra-
diation therapy at an outside institution before referral for
definitive surgery, and another patient received postopera-
tive radiation therapy to the mediastinum after definitive sur-
gical resection because of a positive (microscopic) resection
margin. One patient (patient 16) died of chemotherapy-
related toxicity.
Tumor Recurrence
Three of the 26 patients who underwent R0 or R1 resec-
tion had local recurrences at 5, 16, and 46 months after sur-
gery (Table 3). All local recurrences were in patients with R1
resections; none were in patients with R0 resections. Re-
peated resection was attempted in 2 patients; however, 1 pa-
tient (patient 1) had extensive involvement of the liver and
underwent palliative debulking only. The other patient (pa-
tient 21) had sarcoma recurrence in the left atrium with ex-
tensive right pulmonary vein and lung involvement. This
patient underwent a second cardiac explantation and R0 re-
section that included a right pneumonectomy.
Twelve patients had distant recurrence at a median inter-
val of 10 months from surgery. The most common sites of
distant metastases were the lungs (8 patients), liver (4 pa-
tients), and brain (4 patients; Table 3).
Survival
The 1- and 2- year survivals for the entire patient cohort
(n ¼ 27) were 80.9% (95% confidence interval 60%–
92%) and 61.6% (95% confidence interval 38%–78%), re-
spectively (Figure 1). At a median follow-up of 22 months
(range 2–119 months), 44% (12/27) remain alive. At the
time of follow-up, patients who had undergone resection
with curative intent (R0/R1) and survived surgery (n ¼
24) had a median survival of 23.5 months (range 4–119
months). Patients who had undergone surgical resection, ra-
diofrequency ablation, or radiation treatment for tumor re-
currence (local or metastatic, n ¼ 7) had a median survival
of 47 months (range 16–119 months), whereas patients
with no further intervention for recurrent disease (n ¼ 7)
had a median survival of 25 months (range 8–34 months).
DISCUSSION
Malignant cardiac tumors are rare and usually fatal. Most
are sarcomas that are highly aggressive and locally inva-The Journal of Thoracic and Csive.14,15 There are a few isolated case reports of patient sur-
vival longer than 5 years with less aggressive tumor
histologic types.16 Most published series, including one
from our institution evaluating outcomes from an earlier
time frame, report a dismal prognosis, with fewer than half
of the patients surviving at 1 year.3-11
In this series, most patients were referred with a tissue di-
agnosis established at the referring institution. Most left
atrial sarcomas had been previously resected and thought
to be myxoma before the first surgery and then incompletely
removed. In fact, it can be difficult to distinguish between
a sarcoma and a large myxoma.17 Most right-sided sarcomas
had been sampled for biopsy through a sternotomy (when
the tumor was deemed unresectable) or through a subxiphoid
approach. We recently have begun to use a percutaneous
catheter-based approach to obtain a diagnostic biopsy spec-
imen for patients with tumors in a fashion similar to the bi-
opsy technique used in our transplant population. Most left
ventricular sarcomas and pulmonary artery sarcomas had
the diagnosis presumed preoperatively and confirmed post-
operatively.
Complete surgical resection is crucial for any hope of sur-
vival for the patient.5,11,18-20 Many patients do not undergo
complete resections, partly because of the lack of experience
with extended cardiac resections and partly because of un-
certainty about the diagnosis at the time of the initial surgical
exploration. In this study, nearly two thirds of the patients
referred had undergone previous inadequate surgical inter-
ventions. Although it is technically challenging, the main-
stay of treatment remains en bloc surgical excision.
Our resections were undertaken both for potential cure
and for palliation. Resections for cure required that there
be no evidence of metastatic disease and that the anatomy
of cardiac involvement have the potential for complete re-
section. The entire left and right atria can be resected and re-
constructed. We have found that we can resect about 30% of
the right ventricle and still maintain adequate cardiac func-
tion. Left ventricular resections are possible but carry higher
risk. We believe that the single area that really renders resec-
tion impossible is involvement of the fibrous skeleton of the
heart. Resection for palliation may be undertaken in the pres-
ence of metastatic disease if the control with chemotherapy
is thought possible.
Recently, we have found it clinically beneficial to group
cardiac sarcomas by anatomic location rather than tissue
type when making clinical decisions.21 Right heart sarco-
mas, left heart sarcomas, and pulmonary artery sarcomas
represent our clinical groups.
Most right heart sarcomas are angiosarcomas and tend to
be bulky. They infiltrate the cardiac muscle and metastasize
to the lungs. To achieve negative margins, the entire right
atrium can be resected and reconstructed with bovine peri-
cardium. Surgical management of tumors extending to the
superior or inferior vena cava requires modifications ofardiovascular Surgery c Volume 137, Number 6 1457
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Case
Neoadjuvant
therapy
Adjuvant
therapy Recurrence
Additional
treatments Status
Survival from
dx (mo)
Right heart sarcomas
1 AI Paclitaxel,
doxorubicin, DTIC,
gemcitabine
Local at IVC (5 mo),
brain (39 mo)
Attempted re-resection
IVC (R2 at liver);
resection brain mets
Dead 58
2 Paclitaxel, AI AI, gemcitabine Liver, brain, bone (8 mo) XRT to mets Dead 22
3 Paclitaxel, AI Gemcitabine Liver, remote
mediastinal (2 mo)
None Dead 8
4 None None None None Dead 36
5 None AI Lung (7 mo), brain
(14 mo)
RFA of lung mets,
brain XRT
Dead 24
6 Doxorubicin, DTIC None Lung, abdomen (9 mo) Lung mets resection Alive with disease 16
7 None None NA None Dead 3
8 AI Chest XRT, AI,
paclitaxel, imatinib,
gemcitabine, docetaxel
Lung (16 mo), liver
(29 mo)
Wedge resection of pleural
mets; resection 1 liver
mets, RFA other mets
Alive withdisease 47
9 None AI, paclitaxel Suspicious mass
detected by
computed
tomography
Exploration, resection of
benign scar
NED 40
10 None None Unknown None Dead 10
11 Doxorubicin AI Progression of
existing lung mets
None Dead 30
12 I, epirubicin CHOP Paclitaxel Brain (1 mo) None Alive with disease 2
13 Gemcitabine, taxoterene None None None NED 14
14 Imatinib, epirubicin,
letrozole, gemcitabine,
docetaxel
Gemcitabine, docetaxel Liver, lung (11 mo) None Alive with disease 33
15 None None None None PO death 0.5
16 AIM, gemcitabine, XRT High-dose ifosfamide Lung (6 mo) None Dead (chemotoxicity) 25
17 None None None None PO death 3
Left heart sarcomas
18 AI, dexrazoxane with
growth factors
High-dose ifosfamide None None NED 27
19 Ifosfamide AI LA recurrence, multiple
hilar mets (16 mo)
None Dead 34
20 Ifosfamide High-dose ifosfamide None XRT NED 23
21 Ifosfamide High-dose ifosfamide Cardiac recurrence with
extensive right
pulmonary vein, lung
involvement (46 mo)
Second explantation,
excision of disease
(R0), right
pneumonectomy
Death,
unknown cause
119
22 AI, immunotherapy with
darbapoetin alfa,
pegfilgrastim
None None None NED 20
23 AI Temozolomlide,
doxorubicin
Lung, pelvis (5 mo) None Dead 16
24 None High-dose ifosfamide,
gemcitabine,
interferon-gamma
None None Dead 15
25 None High-dose ifosfamide None None NED 21
Pulmonary artery sarcomas
26 None AI Rib, vertebrae, pelvis
(39 mo)
XRT to mets Alive with disease 75
27 None Gemcitabine, taxoterene None None NED 11
dx, Diagnosis; AI, Adriamycin (doxorubicin), ifosfamide; DTIC, doxycycline, Taxol (paclitaxel), ifosfamide, cyclophosphamide; IVC, inferior vena cava; mets, metastasis; XRT,
external beam radiation therapy; RFA, radiofrequency ablation; NA, not applicable; NED, no evidence of disease; CHOP, cyclophosphamide, hydroxyrubicin, Oncovin (vincris-
tine), prednisone; PO, postoperative; AIM, Adriamycin (doxorubicin), ifosfamide, mesna; LA, left atrial.
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Dcannulation technique or deep hypothermic circulatory ar-
rest. Patients with extensive involvement of the tricuspid
valve undergo valve excision and replacement. Involvement
of the right coronary artery is managed by coronary artery
bypass grafting or reconstruction.
In our experience, malignant fibrous histiocytomas ac-
count for many left heart sarcomas. All but 1 of the left heart
sarcomas in our series required cardiac explantation, ex vivo
tumor resection, and cardiac reconstruction, followed by
cardiac reimplantation. Complete removal of the heart al-
lows excellent visualization of the tumor and surrounding
cardiac structures.
Pulmonary artery sarcomas tend to be angiosarcomas.
Chest computed tomography and magnetic resonance imag-
ing with contrast are the most useful imaging modalities and
supersede echocardiography for defining the tumor location
and extent. In the 2 cases we report here, resection required
replacement of at least some of the pulmonary root and also
required pneumonectomy.
The roles of radiation and chemotherapy in malignant car-
diac tumors are still controversial. Because of the rarity of
the disease, there are no prospective studies to determine
the efficacies of chemotherapy and radiotherapy in addition
to surgery. The limited experience of any single center in the
treatment of cardiac sarcomas makes it difficult to evaluate
the relative importance of these modalities, and extrapola-
tions from the behavior of other soft-tissue sarcomas may
not be applicable.
On the basis of limited reports, however, adjuvant chemo-
therapy does not appear to enhance survival for patients who
have undergone incomplete resections.3,5,11 The combina-
tion of several chemotherapeutic agents appears to be more
effective than single-agent therapy, with ifosfamide, doxoru-
bicin, cyclophosphamide, and paclitaxel all being used with
evidence of response.11,15,16,22,23 A review by Poole and col-
leagues3 has suggested that survival could be enhanced by
postoperative irradiation, but patient numbers were small.
Others have reported a beneficial effect from a combination
of adjuvant chemotherapy and radiotherapy.5,15,16The Journal of Thoracic and CWe believe that neoadjuvant therapy would be helpful in
obtaining clear margins by shrinking the tumor in most pa-
tients, although we have no proof of this. Unfortunately,
most left-sided tumors are first seen with heart failure and re-
quire prompt relief, and chemotherapy does not provide this.
Therefore most left-sided lesions are treated with adjuvant
therapy only. Pulmonary artery sarcoma lesions usually
are first seen with severe right heart failure; they also need
immediate relief and are treated with adjuvant therapy
only. Right heart sarcomas are first seen with a lesser degree
of heart failure but are often larger, more diffuse and infiltra-
tive than pulmonary artery or left sided sarcomas. They are
therefore usually the best candidates for neoadjuvant
therapy.
For recurrent cardiac sarcomas, we have adopted a strat-
egy of aggressive treatment when the recurrence is local or
if the metastatic load is limited. Reasonable survival is
achievable for patients with synchronous metastases, and
surgical treatment of metastatic disease may be worthwhile.
Surgical resection of local recurrence may be formidable but
did produce an example of long-term survival (patient 21).
Radiofrequency ablation and adjuvant treatment for local re-
currence or metastatic disease may also enhance survival.
In our patient cohort, the morbidity and mortality figures
were significant, reflecting the magnitude and complexity of
the surgical procedures. This is an important consideration
when discussing the treatment plan with the patient and in
the informed consent process. In addition, patients should
be educated about the side effects of the various nonsurgical
therapies and the potential complications. The reality is that
these surgical patients tend to be relatively young but unfor-
tunately have a rare cancer that has a poor prognosis.
Limitations
Our study is limited by the small number of patients, and
therefore our findings can only serve as a guide and a contri-
bution toward a better understanding of these rare tumors.
Furthermore, many of our patients were referred from other
hospitals, including international centers; some treatmentardiovascular Surgery c Volume 137, Number 6 1459
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closer to home, although usually with guidance from our in-
stitution. As a result, the details of the follow-up care and
treatment were not always complete.
CONCLUSIONS
With aggressive forms of surgical and multimodal ther-
apy, long-term survival may be achieved in certain cases
of cardiac sarcoma. Obtaining a complete resection should
be the primary goal of the thoracic surgeon, and additional
work on adjuvant therapy for biologic control of the disease
is imperative. Resection and treatment of metastatic and re-
current disease should be considered when possible and may
increase survival.
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